CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 26 enrolled
Drug / intervention
DSXSdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02601469
NCT02601469Phase 2Completed
CompareCT.gov

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients With Plaque Psoriasis.

Sun Pharmaceutical Industries, Inc.·interventional·Posted Nov 10, 2015·Updated Dec 7, 2018

In Brief

A Phase 2 clinical trial evaluating DSXS for Plaque Psoriasis. Completed, enrolled 26 participants across 1 site.

Detailed Summary

An open label, safety study to assess the potential for adrenal suppression following maximal use treatment with DSXS administered twice daily for 28 days in patients with moderate to severe plaque psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 10, 2015
Enrollment StartSep 4, 2015
Primary CompletionDec 29, 2016
Study CompletionAug 25, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.6 years ago

Interventions

DSXSdrug

twice daily for 28 days